



OUR FOCUS
Structure-based
drug discovery
and development

Plexxikon Inc.

Corporate Fact Sheet

JUNE 2010

MANAGEMENT

K. Peter Hirth, PhD

Chief Executive Officer
& Co-Founder

Kathleen Sereda Glaub, MBA

President

Keith B. Nolop, MD

CMO & Senior Vice President
Development

Gideon E. Bollag, PhD

Senior Vice President
Research

Prabha N. Ibrahim, PhD

Vice President
Non-Clinical Development

Gary C. Visor, PhD

Vice President
Pharmaceutics

COLLABORATORS

Roche

Servier

Wyeth

Genentech

BOARD OF DIRECTORS

Joseph P. Schlessinger, PhD

Chairman of the Board
& Co-Founder
Yale University

K. Peter Hirth, PhD

Chief Executive Officer
& Co-Founder

Michael A. Carusi

Advanced Technology Ventures

Jean Deleage, PhD

Alta Partners

David H. MacCallum

Outer Islands Capital

Edward T. Mathers

New Enterprise Associates

About Plexxikon

Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including cardio-renal disease, CNS, inflammation, metabolic disease and oncology. A registration program has been initiated in 2009 for Plexxikon's most advanced program, PLX4032, for the treatment of melanoma. With an option to co-promote PLX4032 in the U.S. as well as a pipeline of oncology opportunities, Plexxikon is laying the foundation for its first commercial franchise—in oncology. Other clinical stage programs include drug candidates for polycystic kidney disease, diabetes, metastatic disease and rheumatoid arthritis. Plexxikon is uniquely positioned to develop multiple commercial franchises for different therapeutic indications, and build significant value for Plexxikon, its collaborators and investors.

Plexxikon's unique discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and partnership deals that secure near term funding and retain significant commercial rights, have been key drivers of the company's success since it began operations in 2001. Plexxikon is seeking collaborations with companies for a number of programs for which it expects to file INDs during the next six to 12 months. The company has signed collaborations with Roche, Servier, Wyeth and Genentech.

PRODUCT PIPELINE

PROGRAM/COMPOUND	INDICATION	PHASE
CARDIO-RENAL DISEASE		
PLX5568	POLYCYSTIC KIDNEY DISEASE	PHASE 1
PROTEASE INHIBITOR	HYPERTENSION	PRECLINICAL
CNS		
PLX5568	PAIN	PHASE 1
KINASE INHIBITOR	MULTIPLE SCLEROSIS	PRECLINICAL
INFLAMMATION		
PLX5622	RHEUMATOID ARTHRITIS	IND-ENABLING
KINASE INHIBITOR	SYSTEMIC LUPUS ERYTHEMATOSUS	PRECLINICAL
METABOLIC DISEASE		
PLX-204	TYPE 2 DIABETES	PHASE 2
NUCLEAR RECEPTOR	OBESITY	PRECLINICAL
ONCOLOGY		
PLX4032	MELANOMA	PHASE 2, 3
PLX4032	COLORECTAL CANCER	PHASE 1
PLX3397	METASTATIC CANCER	PHASE 1

**SCIENTIFIC
ADVISORY BOARD**

Sung-Hou Kim, PhD
Chairman & Co-Founder
University of California,
Berkeley

Axel T. Brunger, PhD
Stanford University

George Demetri, MD
Dana-Farber Cancer Institute

Clayton H. Heathcock, PhD
University of California,
Berkeley

Tony Hunter, PhD
The Salk Institute

C. Ronald Kahn, MD
Harvard University
Medical School

Joseph P. Schlessinger, PhD
Chairman of the Board
& Co-Founder
Yale University

Arthur Weiss, MD, PhD
University of California,
San Francisco

INVESTORS

Advanced Technology Ventures

Alta Partners

Astellas Venture Capital

CW Ventures

Daiwa SMBC Capital

GIMV

Kumho Asiana Group

NIF SMBC Ventures

Pappas Ventures

Walden International

CONTACTS

**BUSINESS DEVELOPMENT
AND INVESTORS**

Kathleen Sereda Glaub
President

Phone: 510.647.4009
Fax: 510.548.8014
kglaub@plexxikon.com

MEDIA

Susan Kinkead
Kinkead Communications
Phone: 415.751.3611
susan@kinkeadcomm.com

Jennifer Cook Williams
Cook Williams Communications
Phone: 360.668.3701
jennifer@cwcomm.org


**Patients and Physicians
Interested in PLX4032 Trials:**

Phone: 1.888.662.6728
Monday-Friday, 9am-5pm (ET)
Email: genentechclinicaltrials@
druginfo.com
www.clinicaltrials.gov

◆◆◆ Plexikon's Lead Program and Oncology Franchise

PLX4032 is a novel, oral and highly selective drug that targets the BRAF gene, a cancer-causing mutation expressed only in tumor cells. This oncogenic mutation occurs in approximately 50 percent of melanomas, approximately 10 percent of colorectal cancers and overall, about eight percent of all solid tumors. In a Phase 1 extension study of mutation-positive metastatic melanoma patients, PLX4032 showed tumor regression in nearly all evaluable patients, with 70 percent of patients showing tumor shrinkage of greater than 30 percent. These results confirmed the preliminary safety and efficacy results seen in a previous Phase 1 dose-escalation study. A second extension study of mutation-positive colorectal cancer patients also recently completed. A pivotal Phase 2 trial was launched in mutation-positive melanoma patients in September 2009, and enrollment is now completed. Additionally, a Phase 3 randomized, controlled study in melanoma began in December 2009.

Plexikon and Roche Pharmaceuticals are co-developing PLX4032 (RG7204) and other selective RAF inhibitors under a license and collaboration agreement signed September 2006, as well as a companion diagnostic alongside this drug.



BRAF MUTATION-POSITIVE PATIENT TREATED ON 320 MG BID

◆◆◆ Advantages of Scaffold-Based Drug Discovery™ Platform

Plexikon's proprietary discovery platform utilizes a number of uniquely integrated technologies. The company begins by screening its scaffold-like compound library, then using structural data to select scaffold candidates and drive chemistry optimization to design potential drug candidates. This process has yielded novel, competitively differentiated drugs that have improved pharmacologic properties. The company has applied its platform approach to multiple drug targets in a number of protein families, including kinases, phosphodiesterases, nuclear hormone receptors and aspartyl proteases.

Plexikon's platform has proven particularly amenable to the development of highly selective, dual or pan modulators, including very selective kinase inhibitors. For a large and significant drug target family such as kinases, designing selective drug candidates provides new and promising treatments in a variety of indications—even outside oncology—where safety hurdles can be much higher.

Plexikon Inc.

91 Bolivar Drive
Berkeley, CA 94710

Phone: 510.647.4000
Fax: 510.548.8014

info@plexxikon.com
www.plexikon.com

